Study: Why even targeted lung cancer therapies eventually fail

Even when patients are treated with targeted cancer therapies, many lung cancer patients suffer a recurrence. Researchers at Cold Spring Harbor Laboratory wanted to uncover how some cancers escape the power of targeted treatment. Their work was published in the journal eLife this week. The team of scientists, lead by Raffaella Sordella, found that a tiny subset of cells in or around a cancerous tumor can change over time and become the seeds of a killer relapse. Get the full story at our sister site, Drug Delivery Business News.   The post Study: Why even targeted lung cancer therapies eventually fail appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Oncology Research & Development Respiratory Cold Spring Harbor Laboratory Source Type: news

Related Links:

In conclusion, the findings demonstrated that 17-DMAG-loaded PCL/PEG nanofibers are more effectual than free 17-DMAG against A549 lung cancer cells via modulation of Hsp90 expression and inhibition of telomerase activity. Hence, the implantable 17-DMAG-loaded nanofibrous scaffolds might be an excellent tool for efficiently killing of the lung residual cancer cells and avoid the local cancer recurrence. PMID: 30021337 [PubMed - in process]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research
In conclusion, our novel formulation destabilized H358 cells by using its acidic tumor microenvironment, thereby regulating cell apoptosis, proliferation, and metastatic properties.
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
Publication date: Available online 19 July 2018Source: Life SciencesAuthor(s): Mohammad Rasheduzzaman, Jae-Kyo Jeong, Sang-Youel ParkAbstractAimsTRAIL is a promising anticancer agent that has the potential to sensitize a wide variety of cancer or transformed cells by inducing apoptosis. However, resistance to TRAIL is a growing concern. Current manuscript aimed to employing combination treatment to investigate resveratrol induced TRAIL sensitization in NSCLC.MethodA549 and HCC-15 cells were used in experimental design. Cell viability was determined by morphological image, crystal violet staining and MTT assay. Apoptosis wa...
Source: Life Sciences - Category: Biology Source Type: research
Kinase inhibitor resistance constitutes a major unresolved clinical challenge in cancer. Furthermore, the role of serine/threonine phosphatase deregulation as a potential cause for resistance to kinase inhibitors has not been thoroughly addressed. We characterize protein phosphatase 2A (PP2A) activity as a global determinant of KRAS-mutant lung cancer cell resistance across a library of>200 kinase inhibitors. The results show that PP2A activity modulation alters cancer cell sensitivities to a large number of kinase inhibitors. Specifically, PP2A inhibition ablated mitogen-activated protein kinase kinase (MEK) inhibitor ...
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Research Articles Source Type: research
Conclusion: Our results indicate that SirT1 regulates apoptosis and radiation sensitization in lung cancer cell lines A549 and H460 via the SirT1/NF- κB/Smac pathway.Cell Physiol Biochem 2018;48:304 –316
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
Work by theNanotechnology Characterization Laboratory (NCL), a joint initiative of NCI, NIST, and the FDA, has led to the discovery of a novel combination chemotherapy. This combination is shown to have synergistic effects on cytotoxicity to cancer cells in vitro, and to cause a substantial decrease in tumor growth in preclinical tumor models in vivo. Combination therapy using these agents may enhance the response rate of different cancers to these drugs and may significantly reduce side effects by permitting a lower therapeutic dose to be administered. SAIC Frederick'' s Nanotechnology Characterization   Laboratory&n...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Conclusion: This article provides a brief current overview of literature pertaining to the role of radiation therapy in the management of lung cancer.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
Conclusion: The approaches of this review are to highlight the recent management advances and contrast the differences of treatment practice between Western and Asian countries.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
Conclusion: In spite of the rapid development of external beam radiation therapy brachytherapy continues to remain an important mode of therapy and is often a default treatment when external beam radiation option is limited.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
Palliation may be the goal of care for some patients with intra-thoracic lung cancer. Factors such as the extent of disease, comorbidities, performance status, or symptom burden, may indicate that patients are unsuitable for more aggressive approaches with a curative intent. A palliative treatment plan implies a focus on the effective relief and control of symptoms, while preserving both the quality and quantity of life. Therapeutic measures may include palliative radiotherapy, palliative chemotherapy, or other forms of systemic treatment. In addition, certain interventional procedures may be used to achieve symptom pallia...
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Laboratory Medicine | Lung Cancer | Respiratory Medicine | Study